Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma

Author:

Yamazaki Naoya1ORCID,Tsutsumida Arata1,Takahashi Akira1,Namikawa Kenjiro1,Yoshikawa Shusuke2,Fujiwara Yutaka3,Kondo Shunsuke4,Mukaiyama Akihira5,Zhang Fanghong5,Kiyohara Yoshio2

Affiliation:

1. Department of Dermatologic Oncology; National Cancer Center Hospital; Tokyo Japan

2. Dermatology Division; Shizuoka Cancer Center Hospital; Shizuoka Japan

3. Experimental Therapeutics; National Cancer Center Hospital; Tokyo Japan

4. Hepatobiliary and Pancreatic Oncology; National Cancer Center Hospital; Tokyo Japan

5. Development Department; Novartis Pharma K.K.; Tokyo Japan

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Dermatology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3